Zydus Lifesciences gets USFDA nod to market Celecoxib capsules, expanding its US portfolio; US sales total $122.6 million.

• Celecoxib treats arthritis, menstrual pain, and juvenile rheumatoid arthritis in children over 2 years old.
• Capsules to be produced at Zydus Lifesciences’ Ahmedabad facility; boosts company’s U.S. generics business.
• With this nod, Zydus holds 428 USFDA final approvals and has filed 492 ANDAs since FY 2003-04.